The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

United Therapeutics Corp

Nasdaq: UTHR
Last

(U.S.) $170.88

Today's change+0.77 +0.45%
Updated July 6 4:00 PM EDT. Delayed by at least 15 minutes.
 

United Therapeutics Corp

Nasdaq: UTHR
Last

(U.S.) $170.88

Today's change+0.77 +0.45%
Updated July 6 4:00 PM EDT. Delayed by at least 15 minutes.

United Therapeutics Corp up (U.S.)$0.77

United Therapeutics Corp closed up Monday by (U.S.)$0.77 or 0.45% to (U.S.)$170.88. Over the last five days, shares are unchanged, but have gained 31.96% over the last year to date. This security has outperformed the S&P 500 by 84.45% during the last year.

Key company metrics

  • Open(U.S.) $169.21
  • Previous close(U.S.) $170.11
  • High(U.S.) $172.15
  • Low(U.S.) $168.31
  • Bid / Ask(U.S.) $160.00 / (U.S.) $186.21
  • YTD % change+31.96%
  • Volume936,734
  • Average volume (10-day)646,991
  • Average volume (1-month)563,853
  • Average volume (3-month)658,115
  • 52-week range(U.S.) $86.04 to (U.S.) $190.29
  • Beta1.55
  • Trailing P/E50.62×
  • P/E 1 year forward23.14×
  • Forward PEG1.18×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $3.38
Updated July 6 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.60%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue328346330323
Total other revenue--------
Total revenue328346330323
Gross profit307331289284
Total cost of revenue21164139
Total operating expense342168362146
Selling / general / administrative2118120368
Research & development1107111940
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-15179-32176
Interest income (expense), net non-operating-2-4-5-5
Gain (loss) on sale of assets--------
Other--------
Income before tax-17175-36173
Income after tax-17116-25112
Income tax, total059-1161
Net income-17116-25112
Total adjustments to net income--------
Net income before extra. items-17116-25112
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-17116-25112
Inc. avail. to common incl. extra. items-17116-25112
Diluted net income-17116-25112
Dilution adjustment--------
Diluted weighted average shares47544753
Diluted EPS excluding extraordinary itemsvalue per share-0.362.17-0.532.10
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.362.17-0.532.10